A group of international experts is proposing a first-of-its-kind framework to prevent multiple sclerosis (MS) from ...

Ryan Haumschild, PharmD, MS, MBA, leads a discussion around the epidemiology of multiple sclerosis. Today, our panel of experts will explore the treatment landscape and impact of multiple sclerosis ...

Multiple sclerosis is a disease that may affect any area of the nervous system, thus causing a wide variety of symptoms such as visual problems, weakness, or numbness. Although the exact cause is ...

DUBLIN--(BUSINESS WIRE)--The "Primary Progressive Multiple Sclerosis (PPMS) - An Overview" report has been added to Research and Markets' offering. The report provides an overview of primary ...

Professional societies of neurologists, including most prominently the American Academy of Neurology (AAN) and the European Academy of Neurology (EAN) periodically release recommendations to guide ...

DUBLIN--(BUSINESS WIRE)--The "Secondary Progressive Multiple Sclerosis (SPMS) - Disease Overview" report has been added to Research and Markets' offering. Detailed overview of the SPMS disease area ...

What Is Late-Onset Multiple Sclerosis? When you have multiple sclerosis (MS), your immune system attacks nerve cells and fibers called axons in your brain. When this happens, your brain can’t send ...

Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.

Use of medical informatics for management of multiple sclerosis using a chronic-care model, pg. 1 The authors describe how the Multiple Sclerosis (MS) Centers of Excellence use healthcare information ...

New results of a 65-year follow-up study of nearly 7,000 Norwegian patients with multiple sclerosis (MS) suggest that patients may have a greater overall risk of developing cancer than the general ...

A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease. To ...